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Summary of doctoral thesis review 
 
Title: Production and characterization of monoclonal antibodies specific for major capsid VP1 protein of 
trichodysplasia spinulosa associated polyomavirus. 
Trichodysplasia spinulosa associated polyomavirus (TSPyV), has been indicated as a causative 
agent of trychodysplasia spinulosa (TS), a rare proliferative skin disease in severly 
immunocompromised hosts. VP1 is the major capsid protein of TSPyV, which functions as a 
potential target for diagnosis of TS disease. The monoclonal antibodies (mAbs) against specific 
antigens have provided the means for developing a number of specific immunological assays for 
rapid and accurate diagnosis of the diseases. So far no good mAb is available for diagnosis of TS 
disease. In this study we developed and characterized the mAbs specific for VP1 of TSPyV. We 
used wheat germ cell-free synthesized VP1 protein of TSPyV for immunizing BALB/c mice to 
generate hybridomas. Screening of the resultant hybridoma clones we selected five strongly 
positive clones producing mAbs reactive to the TSPyV-VP1 antigen. Next we sought to 
characterize these 5 mAbs. Epitope mapping and bioinformatic analysis showed that these mAbs 
recognized epitopes located within highly conserved C-terminal region of all clinical isolates of 
TSPyV-VP1. Further all the mAbs were highly effective for immunofluorescense and 
immunoprecipitation analysis. Among five mAbs, three clones did not exhibit any cross reactivity 
to VP1 of other related polyomaviruses. In addition, one of our mAbs (#14) provided 
immunohistochemical staining of skin tissue of a TS disease. It can be concluded that our newly 
developed mAbs might shed a new light for the study of TSPyV infection as well as the diagnosis 









The questions and answers after presentation of the summary above are as follows: 
 
1. Comments and questions by Dr. Akira Nishiyama: 
(A) The TSPyV develops the highest seropositivity in TS patient. How is this seropositivity 
determined by antigen testing? 
Answer: The previous study used VPI antigen based VLP to determine antibody against TSPyV 
by ELISA for determining the seropositivity. As VP1 is major immunogen to produce antibody, we 
selected VP1 to genereate mAbs. In case of TS disease VP1 based antibody is highest, so VP1 
expression level is also highest. So, the generated mAbs would be able to detect the VP1 antigen 
expressed during TS disease. 
(B) The TSPyV virus causes persistent infection in healthy individual as well as TS disease in 
immunosuppressed individual. Are your mAbs used to determine VP1 antigen in both cases? 
Answer: Previous study demonstrated that VP1 is only detected in TS lesional sample but not in 
non lesional sample. So our mAb would not detect the VP1 from non lesional healthy individual.  
(C) How does persistence develop and why VP1 is not detected in healthy individual? 
Answer: The persistence mechanism of TSPyV is not well understood yet. But other human 
polyomaviruses like JCPyV and BKPyV develop persistent infection by the mechanism that these 
viruses express a single miRNA from late region. This viral miRNA regulate the expression of early 
gene product which ultimately regulate the replication of DNA genome and late gene expression. 
This miRNA also have immune evasion function from host cell. So viral miRNA mediated gene 
expression regulation and immune evasion contribute to the persistence. Some polyomaviruses 
also develop persistence as episomal DNA where no transcription occur. As VP1 is not expressed 
in non lesional skin tissue of healthy individual. it is not detected in such case. 
(D) Why do you co-transfect VP1 and VP2 to the cell for immunoprecipitation analysis? 
Answer: For immunoprecipitation analysis we co-transfected VP1 and VP2 to the cells to identify 
whether VP1 interact with VP2 to form the virus-like particle as well as to get idea whether VP1 
can interact to host proteins to form virus-like particle. 
(E) Why do not you choose VP3? 
Answer: In case of human polyomaviruses, either VP2 or VP3 interact with VP1 to form virus like 
particle and infectious entry of the virus into the cell. Previous study about MCPyV demonstrated 
that VP1 interact with VP2 to form virus-like particle. As TSPyV is similar to MCPyV, we choose 
VP2, not VP3. 
(F)  There are two types of mAbs. Both types recognize C-terminal region of VP1. Is it possible to 
develop sandwitch ELISA using these mAbs? 
Answer: Although the two groups of mAbs recognize the C-terminal region, but they recognize 
different regions without overlapping. So it is possible to develop sandwitch ELISA. 
(G)For sandwitch ELISA, a pair of mAb is required. How can you choose the combination of mAbs? 
Answer: After screening all the possible combinations we will choose the optimal pair which would 
show the highest reactivity. We have two groups of mAbs but one group showed slight cross 
reactivity. So for screening, we would choose cross reactive mAbs as immobilized antibody and 
specific mAbs for labeled antibody. 
(H) How can you generate mAbs if you want to develop another specific group of mAbs which bind 
another epitope region for developing very specific sandwitch ELISA? 
Answer: The same procedure of our previous mAb production method we will follow. After 
producing mAbs, we will perform epitope mapping. If another epitope region will be found, then 
other characterization will be done for selection of specific mAb. 
 
2. Comments and questions by Dr. Yukie Yamaguchi: 
(A) Why do you choose only one antibody for immunohistochemical analysis? 
Answer: We generated five mAbs. Among them two ( #3 and # 12) provided slight cross reactivity 
to JC and BK polyomaviruses. So we excluded these two. Another three (#1, #5 and # 14) mAbs 
bind the same epitope region. We selected only one (#14) because of its higher reactivity in 
immunoblotting and immunofluorescence assay. 
(B) Do you perform other immunoassays using this mAb? 
Answer: I performed the immunohistochemical analysis of healthy skin tissue using this mAb but 
did not perform other immunoassays. 
(C) How does this virus contribute to the pathogenesis of TS disease? 
Answer: TSPyV sT antigen interacts to the tumour suppressor protein PP2A. PP2A is an important 
protein to regulate MAPK mediated cell proliferation and growth. PP2A-sT interaction leads to 
deactivation of PP2A, rendering it incapable of dephosphorylation of MAPKs. So phosphorylated 
MAPKs (pMEK and pERK) are activated and translocated to the nucleus where they transactivate 
the transcriptional gene. Ultimately cell proliferation and growth is occurred. 
(D) Where is this virus found in skin tissue? 
Answer: Hair follicle. 
 
3. Comments and questions by Professor Dr. Yoshihiro Ishikawa: 
(A) The mAbs are used for diagnosis purposes. From where is the sample collected? Is blood or 
other sample used to detect virus using your mAbs? 
 Answer: As TSPyV VP1 expressed exclusively in the hair follicle of skin tissue of TS disease, 
immunohistochemical analysis would be performed using skin tissue to detect VP1 antigen. If 
sandwitch ELISA will be developed, blood, urine, nasopharyngeal swab and skin swab would be 
used to detect the antigen as TSPyV was detected in these sample previously.   
(B) What is the concentration of your mAb to detect the antigen? 
Answer: Actually the concentration of mAb to detect VP1 antigen of TSPyV was not optimized. In 
the future we will measure the concentration. We used culture supernatant (not purified mAb) as 
1:50 dilution in immunoblotting analysis and 1:20 dilution in immunofluorescence analysis. But we 
used the purified mAb as 1:100 dilution in immunohistochemical analysis. 
 
Several other questions were asked, all of which were responded appropriately by the applicant. 
In this study, it was judged that the newly developed monoclonal antibody would play an 
important role in the development of new diagnostic testing against TsPyV. Based on the above, 
the applicant was judged to be suitable for receiving a PhD degree in medical science. 
 
